{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T22:51:47Z","timestamp":1788821507986,"version":"build-2803163510"},"reference-count":37,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2021,6,8]],"date-time":"2021-06-08T00:00:00Z","timestamp":1623110400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>Immune checkpoint inhibitors, approved for the treatment of various types of cancer, are known to cause a unique spectrum of side effects, including acute kidney injury (AKI). The aim of this study was to describe the incidence, risk factors, renal outcomes, and mortality of AKI in patients receiving checkpoint inhibitors.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>Patients receiving checkpoint inhibitors between January 2013 and May 2020 at the University Medical Center Utrecht, the Netherlands, were identified using the Utrecht Patient Oriented Database. AKI was defined as an increase in serum creatinine of \u22651.5 times the baseline value, based on the Kidney Disease: Improving Global Outcomes criteria. Cox proportional hazard regression analysis was used to assess risk factors for AKI and to evaluate the relationship between AKI and mortality. Persistent renal dysfunction was diagnosed in AKI patients with a final serum creatinine measurement of &gt;1.3 times the baseline value.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>Among 676 patients receiving checkpoint inhibitors, the overall incidence of AKI was 14.2%. Baseline variables independently associated with AKI were a gynecologic malignancy, monotherapy with ipilimumab, and the use of a diuretic, angiotensin-converting enzyme inhibitor or angiotensin-receptor blocker, or proton pump inhibitor at baseline. AKI was checkpoint inhibitor-associated in one third of all patients with AKI. Checkpoint inhibitor-associated AKI was mostly low-grade, occurred a median of 15 weeks after checkpoint inhibitor initiation, and resulted in persistent renal dysfunction in approximately 40% of the patients. Patients with all-cause AKI had a twofold increased mortality risk, but checkpoint inhibitor-associated AKI was not associated with increased mortality.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>In this study, patients receiving checkpoint inhibitors frequently developed AKI due to various etiologies. AKI directly related to the effect of checkpoint inhibitor toxicity did not increase mortality. However, AKI not related to the effect of checkpoint inhibitor toxicity was associated with increased mortality.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0252978","type":"journal-article","created":{"date-parts":[[2021,6,8]],"date-time":"2021-06-08T18:26:05Z","timestamp":1623176765000},"page":"e0252978","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":47,"title":["Immune checkpoint inhibitor-associated acute kidney injury and mortality: An observational study"],"prefix":"10.1371","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0559-6881","authenticated-orcid":true,"given":"Marije S.","family":"Koks","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gurbey","family":"Ocak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britt B. M.","family":"Suelmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelia A. R.","family":"Hulsbergen-Veelken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saskia","family":"Haitjema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marieke E.","family":"Vianen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne C.","family":"Verhaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin A. H.","family":"Kaasjager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meriem","family":"Khairoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2021,6,8]]},"reference":[{"issue":"8","key":"pone.0252978.ref001","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"FS Hodi","year":"2010","journal-title":"N Engl J Med"},{"issue":"1","key":"pone.0252978.ref002","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma","volume":"373","author":"J Larkin","year":"2015","journal-title":"N Engl J Med"},{"issue":"31","key":"pone.0252978.ref003","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1200\/JCO.2016.67.3467","article-title":"Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure","volume":"34","author":"P Armand","year":"2016","journal-title":"J Clin Oncol"},{"issue":"2","key":"pone.0252978.ref004","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer","volume":"373","author":"J Brahmer","year":"2015","journal-title":"N Engl J Med"},{"issue":"19","key":"pone.0252978.ref005","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma","volume":"373","author":"RJ Motzer","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"pone.0252978.ref006","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"DM Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"issue":"9","key":"pone.0252978.ref007","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","article-title":"Fundamental Mechanisms of Immune Checkpoint Blockade Therapy","volume":"8","author":"SC Wei","year":"2018","journal-title":"Cancer Discov"},{"issue":"22","key":"pone.0252978.ref008","doi-asserted-by":"crossref","first-page":"6958","DOI":"10.1158\/1078-0432.CCR-11-1595","article-title":"Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma","volume":"17","author":"EJ Lipson","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"1","key":"pone.0252978.ref009","doi-asserted-by":"crossref","first-page":"1860476","DOI":"10.1080\/19420862.2020.1860476","article-title":"Antibodies to watch in 2021","volume":"13","author":"H Kaplon","year":"2021","journal-title":"MAbs"},{"issue":"4","key":"pone.0252978.ref010","doi-asserted-by":"crossref","first-page":"225","DOI":"10.14740\/jocmr3750","article-title":"Adverse Effects of Immune Checkpoint Inhibitors (Programmed Death-1 Inhibitors and Cytotoxic T-Lymphocyte-Associated Protein-4 Inhibitors): Results of a Retrospective Study","volume":"11","author":"R Bajwa","year":"2019","journal-title":"J Clin Med Res"},{"issue":"7","key":"pone.0252978.ref011","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1200\/JCO.2015.66.1389","article-title":"Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma","volume":"35","author":"JS Weber","year":"2017","journal-title":"J Clin Oncol"},{"issue":"7","key":"pone.0252978.ref012","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.2215\/CJN.02340219","article-title":"AKI in Patients Receiving Immune Checkpoint Inhibitors","volume":"14","author":"MA Perazella","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"pone.0252978.ref013","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1634\/theoncologist.2018-0764","article-title":"Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Renal Toxicity: Illustrative Case and Review","volume":"24","author":"ME Sise","year":"2019","journal-title":"Oncologist"},{"issue":"2","key":"pone.0252978.ref014","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1681\/ASN.2019070676","article-title":"Clinical Features and Outcomes of Immune Checkpoint Inhibitor-Associated AKI: A Multicenter Study","volume":"31","author":"FB Cortazar","year":"2020","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"pone.0252978.ref015","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.kint.2016.04.008","article-title":"Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors","volume":"90","author":"FB Cortazar","year":"2016","journal-title":"Kidney Int"},{"issue":"1","key":"pone.0252978.ref016","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s40425-018-0478-8","article-title":"Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience","volume":"7","author":"O Mamlouk","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"1","key":"pone.0252978.ref017","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1159\/000505235","article-title":"Rapidly Progressive Acute Kidney Injury Associated with Nivolumab Treatment","volume":"13","author":"S Okawa","year":"2020","journal-title":"Case Rep Oncol"},{"issue":"1","key":"pone.0252978.ref018","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000467","article-title":"Acute kidney injury associated with immune checkpoint inhibitor therapy: incidence, risk factors and outcomes","volume":"8","author":"A Meraz-Munoz","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"12","key":"pone.0252978.ref019","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.2215\/CJN.00990119","article-title":"The Incidence, Causes, and Risk Factors of Acute Kidney Injury in Patients Receiving Immune Checkpoint Inhibitors","volume":"14","author":"H Seethapathy","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"pone.0252978.ref020","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1515\/CCLM.2007.009","article-title":"Linking laboratory and medication data: new opportunities for pharmacoepidemiological research","volume":"45","author":"MJ ten Berg","year":"2007","journal-title":"Clin Chem Lab Med"},{"issue":"5","key":"pone.0252978.ref021","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"ME Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"pone.0252978.ref022","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejca.2018.09.033","article-title":"Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors","volume":"106","author":"A Moreira","year":"2019","journal-title":"Eur J Cancer"},{"issue":"9","key":"pone.0252978.ref023","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"AS Levey","year":"2009","journal-title":"Ann Intern Med"},{"issue":"1","key":"pone.0252978.ref024","first-page":"1","article-title":"KDIGO Clinical Practice Guideline for Acute Kidney Injury","volume":"2","year":"2012","journal-title":"Kidney Int"},{"issue":"1","key":"pone.0252978.ref025","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1186\/s12882-019-1613-6","article-title":"Evaluation of five different renal recovery definitions for estimation of long-term outcomes of cardiac surgery associated acute kidney injury","volume":"20","author":"J Xu","year":"2019","journal-title":"BMC Nephrol"},{"key":"pone.0252978.ref026","doi-asserted-by":"crossref","first-page":"130","DOI":"10.34067\/KID.0000852019","article-title":"Immune Checkpoint Inhibitor Nephrotoxicity: Update 2020","volume":"360","author":"S Gupta","year":"2020","journal-title":"Kidney"},{"issue":"8","key":"pone.0252978.ref027","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1038\/ki.2008.328","article-title":"Survival analysis: time-dependent effects and time-varying risk factors","volume":"74","author":"FW Dekker","year":"2008","journal-title":"Kidney Int"},{"issue":"10246","key":"pone.0252978.ref028","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0140-6736(20)30540-7","article-title":"The link between kidney disease and cancer: complications and treatment","volume":"396","author":"J Malyszko","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"pone.0252978.ref029","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.kint.2019.07.022","article-title":"Immune checkpoint inhibitor nephrotoxicity: what do we know and what should we do?","volume":"97","author":"MA Perazella","year":"2020","journal-title":"Kidney Int"},{"issue":"5","key":"pone.0252978.ref030","first-page":"500","article-title":"Acute Kidney Injury in Patients with Cancer","volume":"377","author":"MH Rosner","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"pone.0252978.ref031","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1186\/s12882-018-1122-z","article-title":"Female sex reduces the risk of hospital-associated acute kidney injury: a meta-analysis","volume":"19","author":"J Neugarten","year":"2018","journal-title":"BMC Nephrol"},{"issue":"12","key":"pone.0252978.ref032","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/s41581-019-0208-6","article-title":"Sex and the kidneys: current understanding and research opportunities","volume":"15","author":"CN Bairey Merz","year":"2019","journal-title":"Nat Rev Nephrol."},{"issue":"3","key":"pone.0252978.ref033","doi-asserted-by":"crossref","first-page":"F740","DOI":"10.1152\/ajprenal.00049.2017","article-title":"Unique sex- and age-dependent effects in protective pathways in acute kidney injury","volume":"313","author":"R Boddu","year":"2017","journal-title":"Am J Physiol Renal Physiol"},{"issue":"6","key":"pone.0252978.ref034","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1093\/ndt\/13.6.1430","article-title":"Differences between women and men with chronic renal disease","volume":"13","author":"CH Coggins","year":"1998","journal-title":"Nephrol Dial Transplant"},{"key":"pone.0252978.ref035","first-page":"36","article-title":"Correlation between immune-related adverse events (irAEs) and efficacy in patients with solid tumors treated with immune-checkpoints inhibitors (ICIs).","author":"BA Riudavets M","year":"2018","journal-title":"J Clin Oncol"},{"key":"pone.0252978.ref036","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ejca.2018.10.014","article-title":"Immune-related adverse events predict the therapeutic efficacy of anti-PD-1 antibodies in cancer patients","volume":"109","author":"J Rogado","year":"2019","journal-title":"Eur J Cancer"},{"issue":"4","key":"pone.0252978.ref037","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1200\/JOP.18.00005","article-title":"Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline Summary","volume":"14","author":"JR Brahmer","year":"2018","journal-title":"J Oncol Pract"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0252978","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,8]],"date-time":"2021-06-08T18:26:40Z","timestamp":1623176800000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0252978"}},"subtitle":[],"editor":[{"given":"Stanislaw","family":"Stepkowski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,6,8]]},"references-count":37,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,6,8]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0252978","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,8]]}}}